{
  "source": "PA-Notification-Rhofade.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1313-6\nProgram Prior Authorization-Notification\nMedication Mirvaso® (brimonidine gel), Rhofade® (oxymetazoline cream)\nP&T Approval Date 5/2020, 5/2021, 5/2022, 4/2023, 4/2024, 7/2024\nEffective Date 10/1/2024\n1. Background:\nMirvaso (brimonidine) 0.33% topical gel and Rhofade (oxymetazoline) 1% topical cream are\nalpha-adrenergic agonists indicated for the topical treatment of persistent (nontransient)\nerythema of rosacea in adults.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Mirvaso or Rhofade will be approved based on the following criterion:\na. Diagnosis of rosacea\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Mirvaso or Rhofade will be approved based on the following criterion:\na. Documentation of positive clinical response to therapy.\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place\n© 2024 UnitedHealthcare Services, Inc.\n1\n4. References:\n1. Mirvaso [package insert]. Fort Worth, TX; Galderma Laboratories, L.P.; December 2022.\n2. Rhofade [package insert]. Charleston, SC: EPI Health, LLC; November 2019.\nProgram Notification – Rosacea\nChange Control\n5/2020 New program.\n5/2021 Annual review. Updated references.\n5/2022 Annual review. Updated references.\n4/2023 Annual review. Removed requirement of persistent facial erythema.\nAdded state mandate language.\n4/2024 Annual review. Added medical necessity language and updated\nreferenc",
    ". Updated references.\n4/2023 Annual review. Removed requirement of persistent facial erythema.\nAdded state mandate language.\n4/2024 Annual review. Added medical necessity language and updated\nreferences.\n7/2024 Removed step and medical necessity language.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}